223 related articles for article (PubMed ID: 34246651)
1. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data.
Mittal N; Sehray V; Mittal R; Singh S
Eur J Pharmacol; 2021 Sep; 907():174320. PubMed ID: 34246651
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
3. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.
Kim NH; Kim NH
Diabetes Metab J; 2022 Jul; 46(4):543-551. PubMed ID: 35929172
[TBL] [Abstract][Full Text] [Related]
5. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
6. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Giorgino F; Vora J; Fenici P; Solini A
Cardiovasc Diabetol; 2020 Nov; 19(1):196. PubMed ID: 33222693
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
Cherney DZ; Perkins BA
Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
10. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
[TBL] [Abstract][Full Text] [Related]
13. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
Fioretto P; Avogaro A
Expert Opin Pharmacother; 2017 Apr; 18(5):517-527. PubMed ID: 28277831
[TBL] [Abstract][Full Text] [Related]
15. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Dekkers CCJ; Gansevoort RT
Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i33-i42. PubMed ID: 32003836
[TBL] [Abstract][Full Text] [Related]
17. SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus.
Gill A; Gray SP; Jandeleit-Dahm KA; Watson AMD
Curr Diabetes Rev; 2019; 15(5):349-356. PubMed ID: 29663893
[TBL] [Abstract][Full Text] [Related]
18. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]